|
EP0279862B1
(en)
|
1986-08-28 |
1993-11-03 |
Teijin Limited |
Cytocidal antibody complex and process for its preparation
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
AU2010215761B2
(en)
|
2009-02-23 |
2017-04-06 |
Cytomx Therapeutics, Inc |
Proproteins and methods of use thereof
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
MX2017003847A
(es)
*
|
2014-09-25 |
2017-12-15 |
Amgen Inc |
Proteinas biespecificas activables por proteasas.
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
IL292798A
(en)
|
2015-05-04 |
2022-07-01 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
|
|
CA2984892A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
WO2017124002A1
(en)
*
|
2016-01-13 |
2017-07-20 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
MY200695A
(en)
|
2016-11-03 |
2024-01-11 |
Bristol Myers Squibb Co |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
WO2018165619A1
(en)
|
2017-03-09 |
2018-09-13 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
CN111133006A
(zh)
|
2017-07-14 |
2020-05-08 |
西托姆克斯治疗公司 |
抗cd166抗体及其用途
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
|
|
WO2019046652A1
(en)
|
2017-08-30 |
2019-03-07 |
Cytomx Therapeutics, Inc. |
ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE
|
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
WO2019165143A1
(en)
|
2018-02-21 |
2019-08-29 |
Cytomx Therapeutics, Inc. |
Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
|
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス，インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
WO2019213444A1
(en)
|
2018-05-02 |
2019-11-07 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
TWI897855B
(zh)
|
2018-10-26 |
2025-09-21 |
美商免疫遺傳股份有限公司 |
Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
|
|
US20220023439A1
(en)
|
2018-11-02 |
2022-01-27 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd166 antibodies and methods of use thereof
|
|
CA3120327A1
(en)
|
2018-12-06 |
2020-06-11 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
WO2020176672A1
(en)
|
2019-02-26 |
2020-09-03 |
Cytomx Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
|
GB201906685D0
(en)
*
|
2019-05-13 |
2019-06-26 |
Ultrahuman Six Ltd |
Activatable protein constructs and uses thereof
|
|
US20220226514A1
(en)
|
2019-05-17 |
2022-07-21 |
Cytomx Therapeutics, Inc. |
Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
|
|
WO2020252349A1
(en)
|
2019-06-13 |
2020-12-17 |
Cytomx Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
|
|
EP3983440A1
(en)
|
2019-06-13 |
2022-04-20 |
CytomX Therapeutics, Inc. |
Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
|
|
CA3143519A1
(en)
*
|
2019-06-26 |
2020-12-30 |
Volker Schellenberger |
Cd3 antigen binding fragments and compositions comprising same
|
|
JP2022548310A
(ja)
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス，インコーポレイテッド |
抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
|
|
EP4087855A1
(en)
|
2020-01-06 |
2022-11-16 |
CytomX Therapeutics, Inc. |
Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
|
|
JP2023521384A
(ja)
|
2020-04-09 |
2023-05-24 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化可能抗体を含む組成物
|
|
WO2021207669A1
(en)
|
2020-04-10 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|